TSX Shariah screener · October 2026
Is Sernova Biotherapeutics Inc. (SVA) Halal?
Sernova Biotherapeutics Inc. · TSX: SVA · Healthcare
The short answer
No — Sernova Biotherapeutics (SVA) fails this Shariah stock screen. Its Cell Pouch cell-therapy business for type 1 diabetes is permissible, but interest income of C$413 in Q2 2026 (also C$413 in H1 2026) was the company's only income — it is pre-revenue — above the 5% non-compliant income limit. The announced Seraxis merger had not closed as of October 1, 2026 (expected November 2026), so the stock still trades. No Zoya, Musaffa, or ShariaPortfolio rating was found for this ticker — honestly reported as absent, not invented.
Gate 1 — Business activity: PASS
Sernova Biotherapeutics Inc. (TSX:SVA) is a pre-revenue biotech developing the Cell Pouch for type 1 diabetes. A definitive 50/50 merger with Seraxis Holdings was announced September 8, 2026 (renamed BetaNova Biotherapeutics, expected close November 2026 pending a shareholder vote) — it had not closed as of October 1, 2026, and the stock still trades. No alcohol, pork, gambling, conventional interest-based lending, tobacco, cannabis, weapons, or adult-entertainment lines were disclosed. Gate 1 passes. Facts only.
Gate 2 — Debt and cash: Not assessed — income gate decisive
With the income gate failed, the debt ratio does not change the outcome. For reference, the company carries debt (a C$4M loan was repaid in H1 and C$1.49M of convertible debentures were issued; Q2 finance costs were C$920,947), but no debt ratio is asserted here. Market cap was roughly C$51–53M (351,116,814 shares; C$0.14, September 2026). Facts only.
Gate 3 — Non-compliant income: FAIL
The Q2 2026 financial statements (three months ended April 30, 2026) disclose a separate interest-income line of C$413 (also C$413 for H1 2026), while the company is pre-revenue with nil sales. Interest is effectively 100% of the company's income, above the 5% non-compliant income limit. Gate 3 fails. Facts only.
Key figures used
- Interest income: C$413 (Q2 2026) / C$413 (H1 2026) — separately disclosed; revenue nil (pre-revenue)
- Business: Cell Pouch for type 1 diabetes (pre-revenue biotech) — no haram segments
- Seraxis merger announced Sep 8, 2026 (50/50, renamed BetaNova Biotherapeutics, expected close Nov 2026) — NOT closed as of Oct 1, 2026; still trading
- Market cap: ~C$51–53M (351,116,814 shares; C$0.14, Sep 2026); debt figure not asserted (moot)
Frequently asked questions
Is Sernova Biotherapeutics (SVA) halal?
No. Sernova Biotherapeutics fails this Shariah stock screen. Its Cell Pouch cell-therapy business for type 1 diabetes is permissible, but interest income of C$413 in Q2 2026 (also C$413 in H1 2026) was the company's only income — it is pre-revenue — above the 5% limit for non-compliant income. The announced Seraxis merger had not closed as of October 1, 2026 (expected November 2026), so the stock still trades. This is a factual screen, not a religious ruling — consult a qualified scholar for personal guidance.
What is Sernova Biotherapeutics' debt-to-market-cap ratio?
No debt ratio is asserted in this screen: with the income gate failed, the debt ratio does not change the outcome. For reference, the company carries debt (a C$4M loan was repaid in H1 and C$1.49M of convertible debentures were issued), and market cap was roughly C$51–53M in September 2026.
What does Sernova Biotherapeutics do?
Sernova Biotherapeutics Inc. (TSX:SVA) is a pre-revenue biotech developing the Cell Pouch for type 1 diabetes. A definitive 50/50 merger with Seraxis Holdings was announced September 8, 2026 (renamed BetaNova Biotherapeutics, expected close November 2026 pending a shareholder vote) — it had not closed as of October 1, 2026.
How much interest income does Sernova Biotherapeutics earn relative to revenue?
The Q2 2026 financial statements disclose a separate interest-income line of C$413 (also C$413 for H1 2026), while the company is pre-revenue with nil sales. Interest is effectively 100% of the company's income, above the 5% ceiling.
Where can I find more healthcare stock screeners?
See halal-stock-verdicts.html for the full list of stock screeners, including the other healthcare-sector entries.
Sources
Screened 2026-10-01 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.